Kentucky Retirement Systems Insurance Trust Fund acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 5,241 shares of the medical research company's stock, valued at approximately $924,000.
Other hedge funds have also recently modified their holdings of the company. American National Bank & Trust bought a new stake in shares of IQVIA in the 1st quarter worth approximately $26,000. ST Germain D J Co. Inc. grew its position in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in IQVIA during the 4th quarter worth approximately $39,000. Lee Danner & Bass Inc. purchased a new stake in shares of IQVIA in the fourth quarter worth $44,000. Finally, Zions Bancorporation N.A. lifted its position in IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the last quarter. Institutional investors own 89.62% of the company's stock.
IQVIA Stock Up 2.2%
NYSE IQV traded up $3.46 on Tuesday, reaching $158.63. 1,518,393 shares of the stock traded hands, compared to its average volume of 1,647,012. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82. The company has a fifty day moving average price of $148.30 and a 200-day moving average price of $175.41. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The company has a market cap of $27.44 billion, a price-to-earnings ratio of 21.61, a PEG ratio of 1.69 and a beta of 1.28.
IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The firm had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The firm's quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.54 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have weighed in on the stock. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Robert W. Baird reduced their target price on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. UBS Group dropped their target price on IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Citigroup restated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Finally, Hsbc Global Res downgraded IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $226.32.
View Our Latest Report on IQVIA
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Articles
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
